Welcome to our dedicated page for Ligand Pharma news (Ticker: LGND), a resource for investors and traders seeking the latest updates and insights on Ligand Pharma stock.
Ligand Pharmaceuticals Inc. (NASDAQ: LGND) is a biopharmaceutical company that regularly issues news about its royalty portfolio, technology platforms and capital deployment. The company describes its model as enabling the clinical development of high‑value medicines by providing financing, licensing its technologies, or both, and this approach is reflected in its press releases and investor communications.
News about Ligand often covers financial results and guidance, including updates on total core revenue, royalty revenue, Captisol sales, contract revenue and non‑GAAP measures such as core adjusted earnings per diluted share. The company’s announcements highlight how royalty revenue from partnered products such as Filspari, Ohtuvayre, Capvaxive, Qarziba and Zelsuvmi contributes to its outlook, as well as how deployable capital and new royalty investments are expected to influence long‑term royalty receipts.
Investors following LGND news will also see updates on Ligand’s technology platforms and partner programs. Releases describe Captisol‑enabled approvals like Lasix ONYU, developments in programs such as Qtorin rapamycin, and clinical or regulatory milestones reported by partners that may affect Ligand’s royalty streams. In addition, the company reports on financing transactions, including convertible senior notes offerings and amendments to its credit agreement, which provide context on how Ligand funds royalty acquisitions and other strategic investments.
Corporate events such as Investor Day presentations and participation in healthcare and biopharma conferences are another recurring theme in Ligand’s news flow. These events typically feature discussions of strategy, investment activity, the royalty portfolio and long‑term financial outlook. For investors and observers, the LGND news page offers a centralized view of how Ligand’s royalty‑focused business model, technology licensing and capital allocation decisions evolve over time.
Summary not available.
Summary not available.
Ligand Pharmaceuticals (NASDAQ: LGND) will report its first quarter 2023 financial results after the U.S. financial markets close on
Ligand's business model focuses on supporting mid to late-stage drug development through financing and licensing of its platform technologies, such as Captisol and Pelican. The company collaborates with leading pharmaceutical firms including Amgen, Merck, and Pfizer to generate revenue while maintaining a low corporate cost structure.
OmniAb, Inc. (NASDAQ: OABI) reported strong financial results for Q4 and full-year 2022, with Q4 revenue of $35.3 million, up from $15.3 million in Q4 2021, driven by a $25 million milestone from TECVAYLI™ sales. Full-year revenue reached $59.1 million, an increase from $34.7 million in 2021. Despite net losses of $22.3 million for 2022, improved from a loss of $27 million in 2021, the company ended the year with $88.3 million in cash. OmniAb also signed 13 new partnerships and has 69 active partners pursuing 291 programs. The company anticipates recognizing $10 million more in milestone payments in 2023, showcasing a robust pipeline and growth potential.
Ligand Pharmaceuticals (NASDAQ: LGND) reported its financial results for Q4 and full-year 2022, noting total revenues of $50.4 million in Q4 compared to $56.4 million in 2021. Royalties increased to $22 million due to Pelican platform sales. However, core Captisol sales dropped to $3.3 million, and net loss from continuing operations was $14.5 million, or $0.86 per share. For 2023, Ligand raised its financial guidance, expecting total revenues of $120 to $124 million and adjusted EPS of $3.30 to $3.45. The company anticipates significant revenue growth while maintaining a lean cost structure following the spin-out of OmniAb, which occurred on November 1, 2022.
Sermonix Pharmaceuticals and Quantum Leap Healthcare Collaborative announced the inclusion of lasofoxifene in a new study arm of the I-SPY 2 clinical trial, targeting patients with newly diagnosed estrogen receptor-positive invasive cancer. This sub-study, part of the Endocrine Optimization Platform, aims to address high recurrence risks in patients with stage 2/3 ER+/HER2- breast cancer. Lasofoxifene has shown promising results in earlier Phase 2 trials, demonstrating safety and anti-tumor activity. The trial's outcomes may provide insights into improving treatment efficacy and quality of life for breast cancer patients.
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report its fourth quarter 2022 financial results after U.S. markets close on
Ligand Pharmaceuticals (NASDAQ: LGND) announced that its partner Novan, Inc. (NASDAQ: NOVN) has submitted a New Drug Application (NDA) for berdazimer gel, 10.3%, targeting molluscum contagiosum. The FDA approval is anticipated in Q1 2024, pending acceptance of the filing. This gel may become the first FDA-approved treatment for this viral skin infection affecting around 6 million people in the U.S., predominantly children. If approved, Ligand could receive up to
Ligand Pharmaceuticals (NASDAQ: LGND) held an Investor and Analyst Day to review its business model and growth drivers following the successful spin-off of its OmniAb unit. Management highlighted a diverse partnership portfolio and a robust capital deployment strategy, emphasizing M&A opportunities in current market conditions. Key financial guidance for 2023 includes projected core revenue of
Ligand Pharmaceuticals (NASDAQ: LGND) announces John Higgins is retiring as CEO, effective immediately, with Todd C. Davis appointed as his successor. Higgins will remain on the board until December 31, 2022. Under Higgins' leadership, Ligand transitioned to a royalty-based model, now boasting nearly 150 partnered drugs. Davis, with extensive experience in biopharmaceuticals and a successful track record in royalty transactions, aims to enhance shareholder value and oversee strategic growth. An Investor and Analyst Day is scheduled for December 13, 2022, to discuss future plans.
FAQ
What is the current stock price of Ligand Pharma (LGND)?
What is the market cap of Ligand Pharma (LGND)?
